Original Article | Published:

Apoptosis

The proteasome inhibitor bortezomib interacts synergistically with the histone deacetylase inhibitor suberoylanilide hydroxamic acid to induce T-leukemia/lymphoma cells apoptosis

Leukemia volume 23, pages 15071514 (2009) | Download Citation

Abstract

Interactions between inhibitors of the proteasome and histone deacetylases have been examined in human T-leukemia/lymphoma cells both in vitro and in vivo. Co-exposure of cells to bortezomib and suberoylanilide hydroxamic acid (SAHA) synergistically induces T-leukemia/lymphoma cells to undergo apoptosis, consistent with a significant increase in mitochondrial injury and caspase activation. These events are accompanied by inhibition of cyto-protective signaling pathways, including the nuclear factor (NF)-κB, Raf-1/mitogen-induced extracellular kinase (MEK)/extracellular signal-related kinase (ERK) and AKT pathways, and activation of stress-related cascades, including the stress-activated kinases c-jun N-terminal kinase (JNK) and p38 mitogen-activated protein kinase (p38MAPK). Moreover, bortezomib in conjunction with SAHA efficiently induces apoptosis of primary T-leukemia/lymphoma cells and inhibits tumor growth in a murine xenograft model established with subcutaneous injection of Jurkat cells. Taken together, these findings confirm the synergistic anti-tumor effect of the proteasome and histone deacetylase inhibitors, and provide an insight into the future clinical applications of bortezomib–SAHA combining regimen in treating T-cell malignancies.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    , , , , , et al. Acute lymphoblastic leukemia. Hematol Am Soc Hematol Educ Program 2002, 162–192.

  2. 2.

    . Aggressive peripheral T-cell lymphomas (specified and unspecified types). Hematol Am Soc Hematol Educ Program 2005, 267–277.

  3. 3.

    , , , , , et al. Targeting the NF-kappaB signaling pathway in Notch1-induced T-cell leukemia. Nat Med 2007; 13: 70–77.

  4. 4.

    , , , , , et al. Differential expression of NF-kappaB pathway genes among peripheral T-cell lymphomas. Leukemia 2005; 19: 2254–2263.

  5. 5.

    , , . Interleukin-7 in T-cell acute lymphoblastic leukemia: an extrinsic factor supporting leukemogenesis? Leuk Lymphoma 2005; 46: 483–495.

  6. 6.

    , , , , , et al. Oncogenic tyrosine kinase NPM/ALK induces activation of the rapamycin-sensitive mTOR signaling pathway. Oncogene 2007; 26: 5606–5614.

  7. 7.

    , , , , , et al. Activation of mammalian target of rapamycin signaling pathway contributes to tumor cell survival in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma. Cancer Res 2006; 66: 6589–6597.

  8. 8.

    , , , , , . Leukotriene B4 receptor inhibitor LY293111 induces cell cycle arrest and apoptosis in human anaplastic large-cell lymphoma cells via JNK phosphorylation. Leukemia 2005; 19: 1977–1984.

  9. 9.

    , , . p38-MAP kinase activation followed by BIM induction is essential for glucocorticoid-induced apoptosis in lymphoblastic leukemia cells. FEBS Lett 2006; 580: 3539–3544.

  10. 10.

    . The ubiquitin proteasome pathway from bench to bedside. Hematol Am Soc Hematol Educ Program 2005, 220–225.

  11. 11.

    , , , . Treatment with bortezomib in a patient with heavily pretreated refractory T-cell lymphoblastic lymphoma. Eur J Haematol 2006; 77: 445–447.

  12. 12.

    , , , , , et al. Phase II trial of proteasome inhibitor bortezomib in patients with relapsed or refractory cutaneous T-cell lymphoma. J Clin Oncol 2007; 25: 4293–4297.

  13. 13.

    , , , , , . Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer 2001; 1: 194–202.

  14. 14.

    , , , , , et al. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood 2007; 109: 31–39.

  15. 15.

    , , . Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors. Clin Cancer Res 2004; 10: 3839–3852.

  16. 16.

    , , , , , et al. Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in mantle cell lymphoma. Eur J Haematol 2008; 80: 133–142.

  17. 17.

    , , , , , . Interactions between Bortezomib and Romidepsin and Belinostat in chronic lymphocytic leukemia cells. Clin Cancer Res 2008; 14: 549–558.

  18. 18.

    , , , , , et al. In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents. Blood 2001; 97: 1999–2007.

  19. 19.

    , , , , , et al. Prognostic significance of bcl-xL gene expression and apoptotic cell counts in follicular lymphoma. Blood 2004; 103: 695–697.

  20. 20.

    , , , , , et al. Histone deacetylase inhibitors induce remission in transgenic models of therapy-resistant acute promyelocytic leukemia. J Clin Invest 2001; 108: 1321–1330.

  21. 21.

    , , , . NF-kappaB in cancer: from innocent bystander to major culprit. Nat Rev Cancer 2002; 2: 301–310.

  22. 22.

    , . Therapeutic anti-cancer targets upstream of the proteasome. Cancer Treat Rev 2003; 29 (Suppl 1): 49–57.

  23. 23.

    , , . Signal transduction through MAP kinase cascades. Adv Cancer Res 1998; 74: 49–139.

  24. 24.

    , , , , . Inhibition of MEK/ERK signaling synergistically potentiates histone deacetylase inhibitor-induced growth arrest, apoptosis and acetylation of histone H3 on p21(waf1) promoter in acute myelogenous leukemia cell. Leukemia 2008; 22: 1449–1452.

  25. 25.

    , , , . Synergistic interactions between MEK1/2 and histone deacetylase inhibitors in BCR/ABL+ human leukemia cells. Leukemia 2005; 19: 1579–1589.

  26. 26.

    , , . Suberoylanilide hydroxamic acid (SAHA; vorinostat) suppresses translation of cyclin D1 in mantle cell lymphoma cells. Blood 2007; 110: 2667–2673.

  27. 27.

    , , , , , et al. Proteasome inhibition to maximize the apoptotic potential of cytokine therapy for murine neuroblastoma tumors. J Immunol 2006; 176: 6302–6312.

  28. 28.

    , , , , . Ability of the activated PI3K/Akt oncoproteins to synergize with MEK1 and induce cell cycle progression and abrogate the cytokine-dependence of hematopoietic cells. Cell Cycle 2004; 3: 503–512.

  29. 29.

    , . p38 MAP-kinases pathway regulation, function and role in human diseases. Biochim Biophys Acta 2007; 1773: 1358–1375.

  30. 30.

    , , , , , . p38alpha MAP kinase as a sensor of reactive oxygen species in tumorigenesis. Cancer Cell 2007; 11: 191–205.

  31. 31.

    , , , . The hierarchical relationship between MAPK signaling and ROS generation in human leukemia cells undergoing apoptosis in response to the proteasome inhibitor Bortezomib. Exp Cell Res 2004; 295: 555–566.

  32. 32.

    , , , , , et al. Induction of apoptosis in BCR/ABL+ cells by histone deacetylase inhibitors involves reciprocal effects on the RAF/MEK/ERK and JNK pathways. Cancer Biol Ther 2003; 2: 544–551.

  33. 33.

    , , , , , . The proteasome inhibitor bortezomib interacts synergistically with histone deacetylase inhibitors to induce apoptosis in Bcr/Abl+ cells sensitive and resistant to STI571. Blood 2003; 102: 3765–3774.

Download references

Acknowledgements

We thank Professor Arthur Zelent for his critical review of the paper. This work was supported, in part, by the Chinese National Key Program for Basic Research (973:2004CB518600), the Chinese National High Tech Program (863:2006AA02A301 and 863:2006AA02A405), the National Natural Science Foundation of China (30750335), the Shanghai Commission of Science and Technology (08410708800), the Shanghai Rising Star Program (05QMX1429), the Program for New Century Excellent Talents in University, the Scientific Research Foundation for the Returned Overseas Chinese Scholars, the Fok Ying Tung Education Foundation (111035), the Programme de Recherches Avancées, the Samuel Waxman Cancer Research Foundation Laboratory and by the Co-PI Program of Shanghai Rui Jin Hospital/Shanghai Jiao Tong University School of Medicine.

Author information

Author notes

    • Q-L Zhang
    • , L Wang
    • , Y-W Zhang
    •  & X-X Jiang

    These authors contributed equally to this work.

Affiliations

  1. State Key Laboratory of Medical Genomics, Shanghai Institute of Hematology, Shanghai Rui Jin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China

    • Q-L Zhang
    • , L Wang
    • , Y-W Zhang
    • , X-X Jiang
    • , F Yang
    • , W-L Wu
    • , Z Chen
    • , Z-X Shen
    • , S-J Chen
    •  & W-L Zhao
  2. Pôle de Recherches Franco-Chinois en Science du Vivant et Génomique, Laboratory of Molecular Pathology, Shanghai, China

    • Q-L Zhang
    • , L Wang
    • , Y-W Zhang
    • , X-X Jiang
    • , F Yang
    • , W-L Wu
    • , A Janin
    • , Z Chen
    • , S-J Chen
    •  & W-L Zhao
  3. Inserm, U728, Institut d'Hématologie, Hôpital Saint Louis, Université Paris 7-Denis Diderot, Paris, France

    • A Janin

Authors

  1. Search for Q-L Zhang in:

  2. Search for L Wang in:

  3. Search for Y-W Zhang in:

  4. Search for X-X Jiang in:

  5. Search for F Yang in:

  6. Search for W-L Wu in:

  7. Search for A Janin in:

  8. Search for Z Chen in:

  9. Search for Z-X Shen in:

  10. Search for S-J Chen in:

  11. Search for W-L Zhao in:

Corresponding author

Correspondence to W-L Zhao.

About this article

Publication history

Received

Revised

Accepted

Published

DOI

https://doi.org/10.1038/leu.2009.41

Further reading